Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity  by Trivedi, Shubhanshi et al.
Different HIV pox viral vector-based vaccines and adjuvants can induce
unique antigen presenting cells that modulate CD8 T cell avidity
Shubhanshi Trivedi n, Ronald J. Jackson, Charani Ranasinghe
Molecular Mucosal Vaccine Immunology Group, Department of Immunology, The John Curtin School of Medical Research,
The Australian National University, Canberra ACT 0200, Australia
a r t i c l e i n f o
Article history:
Received 11 June 2014
Returned to author for revisions
4 August 2014
Accepted 6 September 2014
Available online 28 September 2014
Keywords:
HIV vaccines
CD8þ T cell avidity
IL-13Rα2/IL-4R antagonist
Poxvirus vectors
Lung dendritic cells
a b s t r a c t
The lung-derived dendritic cell (LDC) recruitment following intranasal (i.n.) vaccination of different
poxviral vector-based vaccines/adjuvants were evaluated to decipher how these factors inﬂuenced
CD8þ T cell avidity. Compared to the standard i.n. recombinant fowlpox virus (FPV)-HIV vaccination,
the FPV-HIV IL-13Rα2 or IL-4Rα antagonist adjuvanted vaccines that induced higher avidity CD8þ T
cells, also recruited signiﬁcantly elevated MHCIIþ CD11cþ CD11bþ CD103 CD64 MAR-1 conven-
tional DC (cDCs) to the lung mucosae (hierarchy: IL-4R antagonist4 IL-13Rα24unadjuvanted). In
contrast, elevated CD11b CD103þ LDCs were detected in animals that received recombinant HIV
vaccinia virus (rVV) or Modiﬁed Vaccinia Ankara virus (MVA) vector-based vaccines. Adoptive transfer
studies indicated that CD11b CD103þ LDCs signiﬁcantly dampened HIV-speciﬁc CD8þ T cell avidity
compared to CD11bþ CD103 LDCs. Collectively; our observations revealed that rFPV vector prime and
transient inhibition of IL-4/IL-13 at the vaccination site favoured the recruitment of unique LDCs,
associated with the induction of high quality immunity.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Recombinant viral vectors have been trialed as vehicles to
deliver vaccines antigens against many pathogens such as HIV/
AIDS, tuberculosis and malaria (Benlahrech et al., 2009; Boyle and
Coupar, 1988; Buchbinder et al., 2008; Coupar et al., 2006; Gomez
et al., 2013). Different viral vectors and their combinations as well
as the vaccine cell milieu have been shown to signiﬁcantly
inﬂuence vaccine efﬁcacy (Kent et al., 2005; Pillai et al., 2011;
Ranasinghe et al., 2011). It has now been established that according
to the site of pathogen encounter and the anatomical location
(example skin or lung) the antigen presenting cell subsets (APC)
recruited or activated can be vastly different resulting in varying
immune responses (Ballesteros-Tato et al., 2010; Beauchamp et al.,
2010; Bedoui et al., 2009; Belz, 2004b; Guilliams et al., 2013;
Hervouet et al., 2014; Lee, 2009).
Recently, lung dendritic cells (LDCs) have been categorized into
four major subsets according to the expression of the cell surface
markers and development (Desch et al., 2013; Lambrecht and
Hammad, 2012). In the steady state, LDCs can be subdivided into
plasmacytoid DCs (pDCs) (Heath and Carbone, 2009) and two
migratory conventional DC (cDC) populations, distinguished by the
expression of either CD103 (CD103þ LDC) or CD11b (CD11bþ LDC)
(Sung et al., 2006). Under inﬂammatory conditions, CD11bþ
monocyte-derived DCs (moDCs, CD64þ MAR-1þ) are recruited
to lung mucosae (Plantinga et al., 2013). Similarly, lung macro-
phages fall into two categories, the well-deﬁned alveolar macro-
phages (AMFs) and the less deﬁned interstitial macrophages
(IMFs) (Landsman and Jung, 2007). Recent studies have demon-
strated that different DC subsets can have different functional
capabilities; for example, CD103þ LDCs cross-present exogenous
viral antigen to CD4þ and CD8þ T cells (del Rio et al., 2007) and
promote viral clearance (Geurts van Kessel et al., 2008), while
CD11bþ LDCs have a role in stimulation of CD4þ T cell responses
and production of proinﬂammatory chemokines (Beaty et al.,
2007). At the peak of inﬂuenza virus infection CD11bþ DCs have
been shown to cross-prime CD8þ T cells in the draining lymph
nodes (Ballesteros-Tato et al., 2010) but whether these DCs are
mainly moDCs or CD11bþ cDCs has not been well established.
During herpes simplex virus infection moDCs have been shown to
prime Th1 cell immunity (Iijima et al., 2011), moDCs have also
been shown to play a proinﬂammatory role in asthma (Plantinga
et al., 2013). Thus, it is thought that the functional differences of
lung-derived DC subsets may vary according to the environment
and pathogens they encounter.
HIV is a disease of mucosae and thus, induction of good
mucosal CD8þ T cell immunity at the ﬁrst line of defense is
thought to be pivotal for the effective control of the disease
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(Shacklett and Ferre, 2011; Veazey et al., 1998). Our previous
studies have shown that rFPV is an excellent mucosal delivery
vector compared to recombinant DNA or VV (Kent et al., 2005;
Ranasinghe et al., 2011). FPV (Poxviridae, genus Avipoxvirus) is
restricted to growth in avian species and undergoes abortive
replication in mammalian cells expressing early and late viral
products but no mature infectious virus (Somogyi et al., 1993).
Previous studies have clearly established that systemic delivery of
rFPV vector-based vaccines are extremely safe in humans and does
not cause any adverse effects (Kelleher et al., 2006; Skinner et al.,
2005).
Many studies have shown that different poxviral vector combi-
nations in a prime-boost vaccination setting can induce varying
immune outcomes (Ranasinghe et al., 2006; Wijesundara et al.,
2014). In addition, studies have shown that compared to systemic
vaccination, mucosal immunization can induce high-avidity CD8þ
T cells with better protective efﬁcacy against HIV-1 (Belyakov et al.,
2006; Ranasinghe et al., 2007). Our studies have shown that lower
IL-4 and IL-13 expression by HIV-speciﬁc CD8þ T cells is associated
with the induction of high avidity CD8þ T cells (Ranasinghe and
Ramshaw, 2009; Ranasinghe et al., 2007). More importantly high
avidity HIV-speciﬁc CD8þ T cells have been detected in HIV elite
controllers (Betts et al., 2006), demonstrating the importance of
inducing high avidity CD8þ T cells following HIV-1 vaccination.
Our recent studies have indicated that compared to a standard
intranasal (i.n) FPV-HIV prime followed by intramuscular (i.m.)
VV-HIV booster vaccination strategy, i.n. FPV-HIV IL-13Rα2/ i.m.
VV-HIV IL-13Rα2 or i.n. FPV-HIV IL-4R antagonist/i.m. VV-HIV
IL-4R antagonist adjuvanted vaccine strategies can induce robust
high avidity mucosal and systemic HIV-speciﬁc CD8þ T cells with
better protective efﬁcacy following a surrogate mucosal challenge
(Jackson et al., 2014b; Ranasinghe et al., 2013). These vaccine
induce high avidity T cell immunity by transiently sequestering IL-
13 (Ranasinghe et al., 2013) or inhibiting both IL-4 and IL-13 cell-
signaling at the vaccination site respectively (Jackson et al., 2014b;
Ranasinghe et al., in press). Our studies also have demonstrated
that inclusion of the inhibitors (soluble IL-13Rα2 or IL-4R antago-
nist) in the priming vaccination was essential to induce a high
avidity T cell repertoire (Jackson et al., 2014b; Ranasinghe et al.,
2013). Interestingly, an elegant study by Kroger and co-workers
have implicated that DCs play an important role in modulating the
avidity of T cells (Kroger et al., 2008). So far, which different
antigen presenting cell (APC) subsets are directly involved in
modulating T cell avidity is not fully characterized.
Therefore, in the current study, we have investigated (i) how
and why i.n. delivery of rFPV vaccines induce high avidity mucosal
and systemic T cell immunity compared to the i.n. delivery of rVV
or the highly attenuated rMVA vaccine vectors, (ii) what APC
subsets are induced/recruited to the lung mucosae following our
novel IL-4/IL-13 inhibitor HIV-1 vaccines compared to the standard
vaccination and (iii) more speciﬁcally which lung DC subsets are
involved in inducing high avidity HIV-speciﬁc CD8þ T cells at the
lung mucosae.
Results
Intranasal delivery of IL-4 and/or IL-13 inhibitor vaccines induces
unique APC recruitment to the lung mucosae.
Recently, we have shown that HIV-vaccines that “transiently”
block IL-13 activity (FPV-HIV IL-13Rα2) at the lung mucosae can
induce high-avidity CD8þ T cells and recruit large numbers of
unique APC subsets to the lung mucosae (Ranasinghe et al., 2013).
Hence, in this study, 24 h post i.n. immunization with IL-13Rα2
adjuvanted vaccine the numbers of IAdþ , CD11cþ CD11bþ DCs in
the lung mucosae were assessed using immunoﬂuorescent stain-
ing. The 24 h time point was selected as we have found that peak
rFPV gene expression occurs between 12–24 h post immunization
(Trivedi et al., unpublished). Data revealed that mice that received
FPV-HIV IL-13Rα2 vaccine induced an elevated CD11bþ DC subset
in the lung mucosae compared to the mice that received FPV-HIV
vaccine (Fig. 1). To address this further and identify the speciﬁc DC
subset that may play a role in modulating T-cell avidity, mice
were immunized with standard unadjuvanted vaccine (FPV-HIV),
IL-13Rα2 or IL-4Rα antagonist adjuvanted vaccines as indicated in
methods. 24 h post vaccination lung single-cell suspensions were
prepared and were stained for MHCII IAd, CD11c, CD11b, F4/80,
CD103, B220, CD8 and CD86 and data were analyzed using 8-color
ﬂow cytometry as described in methods (Supplementary Fig. 1 for
the gating strategy). Although there were no signiﬁcant differ-
ences in the percentages and overall numbers of MHCIIþ and/or
Fig. 1. Three color immunoﬂuorescent staining of antigen presenting cells (APC's) in lung. 24 h post intranasal immunization with either (i) FPV-HIV vaccine or (ii) FPV-HIV
IL-13Rα2 adjuvanted vaccine, frozen sections of lungs were stained with antibodies against MHCII IAd, CD11c, and CD11b and images were captured using confocal
microscope. In representative lung sections, green immune-staining indicates MHCII IAd expression, blue—CD11cþ cells and red—CD11bþ cells respectively. Extreme right
plots indicate the overlay of all channels. The experiments were repeated twice, each image is a representative of 3–5 animals.
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Fig. 2. Evaluation of APC subsets in lung following standard or IL-13 and/or IL-4 inhibitor vaccines. BALB/c and IL-13 KO mice were immunized i.n. with FPV-HIV
unadjuvanted vaccine and a second group of BALB/c mice were immunized with FPV-HIV IL-13Rα2 or FPV-HIV IL-4C118 adjuvanted vaccines. 24 h post i.n. immunization, the
lungs were harvested and cells were stained as described in methods (due to small sample size, lungs from 3 animal were pooled and staining was performed). (a) FACS plots
were pre-gated on IAdþ and CD11cþ population as explained in supplementary ﬁgure 1. IAdþ and CD11cþ cells were further analyzed for cell surface expression of
(i) CD11b, CD103; (ii) CD11b, F4/80; (iii) CD11b, CD8 and (iv) CD11b, B220, (v) The graphs represent mean of six independent experiments (total 18 mice) and error bars
represent standard error of mean and p-values were determined using two-tailed, two sample equal variance Student's t-test. (b) Histograms show the surface expression
levels of CD8, F4/80, B220 and CD86 pre-gated on MHCII IAdþ CD11cþ CD11bþ CD103 LDCs. In the histogram plots the four vaccinated group are indicated as; blue ﬁlled—
FPV-HIV unadjuvanted control vaccine group; green line—FPV-HIV IL-13Rα2 adjuvanted vaccine group; red line—FPV-HIV IL-4 Rα-antagonist adjuvanted vaccine group; gray
—IL-13 KO mice that received FPV-HIV vaccine and the open black represent the ﬂuorescence minus one (FMO) control for the indicated marker. (c) CD11bþ DCs pre-gated
on MHCIIþ CD11cþ cells were further analyzed using CD64, MAR-1, Ly-6C (to distinguish moDCs from cDCs) and Siglec-F (to distinguish DCs from AMFs). The numbers in the
upper right quadrants indicate the cell counts (which are indicated within brackets) and the percentage of CD11bþ CD64þ , CD11bþ MAR-1þ , CD11bþ Ly-6Cþ and CD11bþ
Siglec-Fþ cells out of the total CD11bþ LDC population. (d) After doublet discrimination, lungs AMFs were deﬁned as Siglec-Fþ CD11b. The extreme right FACS plot indicate
the gates used to identify the AMF population based on the Siglec-F FMO control. Histograms show the surface expression levels of CD11c, F4/80 and MHCII pre-gated on
Siglec-Fþ CD11b alveolar macrophages. Blue ﬁlled line indicates the FPV-HIV vaccinated group, the red line indicated the FPV-HIV IL-4C118 (IL-4Rα-antagonist adjuvanted)
vaccine group and the open black dotted line indicates the FMO control. The experiments described in Figs. 2c and d were repeated twice.
S. Trivedi et al. / Virology 468-470 (2014) 479–489 481
Fig. 2. (continued)
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MHCIIþ CD11cþ populations between the standard vaccine and
IL-13 and/or IL-4 inhibitor vaccines (Supplementary Fig. 2(part A)),
when the MHCII IAdþ CD11cþ LDC subsets were further analyzed,
substantial differences between the vaccination groups were
detected (Fig. 2). Note that the percentages and numbers of
MHCIIþ CD11cþ populations were signiﬁcantly enhanced in all
the vaccinated groups tested compared to the unimmunized
animals (Supplementary Fig. 2(part A)). Speciﬁcally, data revealed
that compared to the lung samples obtained from wild type (WT)
BALB/c mice, the IL-13 knock-out (KO) mice that received standard
vaccine (FPV-HIV), the WT BALB/c mice that received the novel IL-
13Rα2 adjuvanted vaccine (FPV-HIV IL-13Rα2) or the IL-4Rα
antagonist adjuvanted vaccine (FPV-HIV IL-4C118) showed greatly
enhanced CD11bþ CD103 , CD11bþ CD8 , CD11bþ F4/80þ and
CD11bþ B220 LDC subsets (Fig. 2(a) and Supplementary Fig. 2
(part B) for background percentages of DC subsets obtained from
unimmunized mice). Moreover, IL-4Rα antagonist adjuvanted
vaccine that inhibits both IL-4 and IL-13 activity at the vaccination
site showed signiﬁcantly elevated CD11bþ CD103 DC recruit-
ment to the lung mucosae compared to the standard vaccine
(standard vaccine vs. IL-4Rα antagonist vaccine, p¼0.014) (Fig. 2
(a)). Interestingly, when the CD11bþ CD103 LDC subset was
further analyzed data revealed that this population was CD8α and
B220 negative but F4/80 and CD86 positive (Fig. 2(b)) suggesting
that IL-4Rα antagonist adjuvanted vaccine recruited higher num-
bers of CD11bþ CD103 CD8α B220 F4/80þ CD86þ DCs to the
lung mucosae compared to the standard vaccine.
We next sought to identify whether this elevated CD11bþ DC
subset following IL-4Rα antagonist adjuvanted vaccination was
mainly cDCs or moDCs using CD64 and MAR-1 surface staining.
Data revealed that 97% of CD11bþ DC population was CD64
and/ MAR-1 indicating that these were cDC and not moDC
(CD64þ and/ MAR-1þ) (Fig. 2(c)). Although, the total numbers of
CD11bþ CD64þ / CD11bþ MAR-1þ moDCs were found to be
Fig. 3. Evaluation of APC subsets in the lung mucosae following intranasal delivery of different recombinant poxvirus vector-based vaccines. BALB/c mice were immunized i.
n. with FPV-HIV unadjuvanted vaccine or with VV-HIV or with MVA-HIV vaccine and 24 h post vaccination lung cells were stained as described in methods. FACS plots
display cells pre-gated on MHCII IAdþ and CD11cþ population. MHCIIþ and CD11cþ population of cells were further analyzed for cell surface expression of (i) CD11b, CD103;
(ii) CD11b, F4/80; (iii) CD11b, CD8 and (iv) CD11b, B220. (v) The graphs represent mean of ﬁve independent experiments for FPV-HIV (total 15 mice) and 3 to 4 experiments
for VV-HIV and MVA-HIV vaccines (total 9–12 mice). The error bars represent standard error of the mean. To obtain enough cells, in each experiment the lungs from three
mice were pooled, and the experiments were repeated 3 to 5 times as indicated above.
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higher in the IL-4Rα antagonist adjuvanted vaccine, the overall
percentages were similar to that of the standard unadjuvanted
vaccine (Fig. 2(c)). Our results also further conﬁrmed that mono-
cytic Ly-6C marker (expressed temporarily when monocytes
differentiate into DCs) is not a reliable marker to discriminate
moDCs from cDCs (Fig. 2(c)), which is consistent with recent
ﬁndings (Plantinga et al., 2013). Furthermore, when the CD11bþ
population was further evaluated using Siglec-F, 90% of the
CD11bþ population was found to be Siglec-F indicating that they
were not alveolar macrophages (AMFs) (Fig. 2d). We next used the
gating strategy described by Misharin et. al. to further identify the
AMFs (Misharin et al., 2013). Data further revealed that the lung
AMF (MHCII CD11cþ CD11b Siglec-Fþ and F4/80þ) subset was
decreased in mice that received IL-4Rα antagonist adjuvanted
vaccination compared to the standard FPV-HIV vaccination (Fig. 2
(d)).
Intranasal delivery of rFPV can recruit unique APC subsets to the lung
mucosae compared to other recombinant pox viral vectors.
Our previous studies have also shown that choice of recombi-
nant poxvirus vector combination and the order in which they are
administrated can greatly inﬂuence the antigen-speciﬁc T cell
immunity and also T cell avidity (Kent et al., 2005; Ranasinghe
et al., 2011, 2006; Wijesundara et al., 2014). These studies have
shown that rFPV given in the prime compared to rVV can induce
better immune outcomes in terms of HIV-speciﬁc CD8þ T cell
avidity. Thus, we then evaluated whether different poxvirus
vectors can recruit different APC subsets to the lung mucosae.
Mice were immunized i.n. with FPV-HIV, VV-HIV and MVA-HIV
and 24h post vaccination the LDC subsets were evaluated. Similar
to the results above (Supplementary Fig. 2(part A)) no signiﬁcant
differences were observed in the total MHCIIþ and/or or MHCIIþ
CD11cþ populations. However, following VV-HIV or MVA-HIV
vaccination, the CD11b CD103þ lung DC subset was markedly
enhanced in comparison to mice that received the unadjuvanted
FPV-HIV vaccination (FPV-HIV vs. MVA-HIV, p¼0.001) (Fig. 3).
In this study we also conﬁrmed that the CD103þ DC population
did not contain T cells as this population was CD3 CD8
(Supplementary Fig. 2 (part C), (also when the CD3þ population
was gated out and analysis was performed similar results were
observed). Furthermore, the BALB/c mice that received the unad-
juvanted FPV-HIV vaccine, CD11b B220þ LDC subsets were
signiﬁcantly reduced compared to the groups that received VV-
HIV or MVA-HIV vaccination (FPV-HIV vs. MVA-HIV, p¼0.0008)
(Fig. 3). Unlike IL-13 and/or IL-4 inhibitor vaccines, there were no
signiﬁcant differences in CD11bþ F4/80þ and CD11bþ CD8 LDC
subsets between vectors. Also, in the animals that received MVA-
HIV or VV-HIV, CD11b F4/80þ APC subset appeared to be
enhanced compared to the animals that received FPV-HIV
(Fig. 3) or FPV-HIV IL-4Rα antagonist adjuvanted vaccines (Fig. 2
(a)), whether this APC subset is a true macrophage population
warrants further investigated.
CD11b CD103þ LDCs can dampen the HIV-speciﬁc CD8þ T cell
avidity following immunization.
Following FPV-HIV IL-4Rα antagonist adjuvanted vaccination, a
20% increase in the recruitment of CD11bþ CD103 LDCs to the
lung mucosae were detected compared to the standard unadju-
vanted FPV-HIV vaccine (Fig. 2(a)). In contrast, MVA-HIV and VV-
HIV vaccines, which have shown to be poor inducers of high
avidity CD8þ T cells following i.n. delivery, also recruited higher
numbers of CD11b CD103þ DCs to the lung mucosae (Fig. 3).
Thus, we next tested which LDC subset(s) is/are involved in
modulating the CD8þ T cell avidity. 24 h post i.n. immunization
with FPV-HIV IL-4Rα antagonist vaccine, single-cell lung suspen-
sions were prepared and after staining as before, CD11bþ CD103
Fig. 3. (continued)
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and CD11b CD103þ LDCs were sorted and 1105 cells were
intranasally transferred into two WT BALB/c mice groups (n¼3).
A control group was given similar volume of PBS i.n. and sixteen
hours following post LDC transfer, the mice were i.n. primed with
FPV-HIV and two weeks later intramuscular (i.m.) boosted with
MVA-HIV. Fourteen days post boost immunization, when spleens
were harvested and analyzed for H2-KdGag197–205 tetramer stain-
ing no signiﬁcant differences in the magnitude of the KdGag197–205
-speciﬁc CD8þ T cells were observed between the control and
CD11bþ CD103 LDCs or CD11b CD103þ LDCs transferred
groups (Fig. 4(i)). However, when tetramer dissociation assays
were performed, mice that received CD11b CD103þ LDCs
showed much faster dissociation rate and generated lower avidity
HIV-speciﬁc CD8þ T cells compared to the mice that received only PBS
control prior to prime-boost vaccination (*p¼0.038) (Fig. 4(ii)).
Furthermore, the mice that received CD11bþ CD103 LDC showed
similar HIV-speciﬁc CD8þ Tcell avidity to that of the control (Fig. 4(ii)).
Note that in general our studies have shown that CD8þ T cell
responses observed with i.n./i.m. FPV-HIV/VV-HIV and FPV-HIV/
MVA-HIV are almost identical (Ranasinghe and Jackson, unpublished
observations).
Discussion
Several studies have now clearly established that mucosal HIV
vaccines offer better protective efﬁcacy compared to systemic
delivery (Belyakov et al., 1998; Kent et al., 2005; Kozlowski and
Neutra, 2003). Our studies have revealed that i.n. priming with
rFPV co-expressing IL-13Rα2 (Ranasinghe et al., 2013) or IL-4Rα
antagonist adjuvants (Jackson et al., 2014b) together with HIV
antigens can initiate high avidity systemic and mucosal HIV-
speciﬁc CD8þ T cell immunity. Current study demonstrated that
temporary inhibition of IL-4 and/or IL-13 cytokine function at the
vaccination site can greatly enhance CD11bþ CD103 , CD11bþ
CD8 , CD11bþ F4/80þ and CD11bþ B220 LDC subsets compared
to the standard unadjuvanted FPV-HIV vaccination. More interest-
ingly, the LDC recruitment following IL-13Rα2-adjuvanted vacci-
nation was similar to an IL-13 KO animal given the standard
FPV-HIV vaccination showing the potent transient effect of
IL-13Rα2 co-expression in an rFPV vector-based vaccination setting.
To our understanding, this is ﬁrst study to demonstrate that the
number of CD11bþ , CD103þ cDCs and moDCs recruited to lung
mucosae following vaccination is inﬂuenced by IL-4/IL-13 cytokine
in the cell milieu. In addition, the poxvirus vaccine vectors used
can also signiﬁcantly inﬂuence the proportions of recruited DC
populations affecting the adaptive immune outcomes and the
efﬁcacy of a vector-based HIV vaccine. DC subsets that generally
cross-prime CD8þ T cells are known to be CD8αþ (Belz, 2004a;
den Haan et al., 2000). However, in some instances CD8α cDCs
have also been shown to directly participate in cross-presentation
and/or cross-dressing of exogenous antigen to initiate CD8þ T cell
responses (den Haan and Bevan, 2002; Moron et al., 2002; Smyth
et al., 2012). In this study the CD11bþ CD103 CD8α cDC subset
was highly elevated in animals receiving the IL-13Rα2 or the
IL-4Rα antagonist adjuvanted vaccines suggesting that this cDC
population may be involved in inducing high avidity polyfunc-
tional (IFN-γþ , TNF-αþ and IL-2þ) CD8þ T cells. In addition to the
CD11bþ cDCs, moDCs were also found to be elevated in animals
that received the IL-4Rα antagonist adjuvanted vaccine compared
to the standard vaccine. Interestingly, in bacterial, parasitic, fungal
and viral infectious models moDCs have been associated with Th1
cell mediated immunity (Hohl et al., 2009; Leon et al., 2007;
Nakano et al., 2009). In contrast, the number of AMFs detected in
lung (deﬁned as Siglec-Fþ CD11cþ F4/80þ MHCII CD11b)
following IL-4Rα antagonist adjuvanted vaccine was greatly
reduced compared to the standard FPV-HIV vaccine which is not
entirely surprising as AMFs are known to be relatively ineffective
at priming naïve CD8þ T cells (Lipscomb et al., 1986). The elevated
cDCs observed following the IL-4Rα antagonist adjuvanted vaccine
suggest that blocking STAT6 pathway and/or IL-13 signaling via the
IL-13Rα2 membrane-bound receptor pathway (Tabata and
Khurana Hershey, 2007) play an important role in DC modulation
at the vaccination site.
Several studies have demonstrated that the vector combination
can also play a signiﬁcant role in modulating HIV-speciﬁc CD8þ T
cell immunity in terms of avidity or memory CD8þ T cell
differentiation (Kent et al., 2005; Pillai et al., 2011; Ranasinghe et
al., 2011; Ranasinghe et al., 2006). For example; MVA prime and
adenovirus vector type 5 (Ad5) booster vaccination strategy was
shown to generate HIV-speciﬁc CD8þ T cells with central memory
phenotype whilst Ad5/MVA prime-boost vaccination was shown
to generate effector memory CD8þ T cells (Pillai et al., 2011).
In another study, compared to Ad/Ad prime-boost vaccination, an
Ad/vesicular stomatitis virus vector prime-boost vaccination strat-
egy was shown to induce poor protective efﬁcacy against tuber-
culosis (Jeyanathan et al., 2013). Our studies have shown that
whilst i.n. FPV-HIV/ i.m. VV-HIV strategy can induce robust
sustained high magnitude polyfunctional HIV-speciﬁc mucosal/
systemic CD8þ T cells, i.n. or i.m. vaccinia virus priming followed
Fig. 4. Avidity of HIV-speciﬁc CD8þ T cells following adoptive transfer of different dendritic cells. 1105 CD11bþ and CD103þ LDCs were transferred from FPV-HIV IL-4Rα
immunized BALB/c mice (n¼14) into recipient BALB/c mice (n¼3 to 4 per group in each experiment) as mentioned in methods. (i) The number of HIV-speciﬁc splenic CD8þ
T cells in FPV-HIV/MVA-HIV (i.n./i.m.) immunized control BALB/c mice (gray bar), CD11bþ LDC recipient mice (bar ﬁlled with pattern) and CD103þ LDC recipient mice (black
bar) were evaluated 14 days post booster vaccination. (ii) At the same time, percentage of Kd gag197–205—positive CD8þ splenocytes loss (dissociation) was measured as
described in methods. Error bars represent meanþstandard error of mean of the two independent experiments.
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by i.m. FPV-HIV booster vaccination induced lower numbers of
HIV-speciﬁc CD8þ T cells that produced only IFN-γ or TNF-α
(Ranasinghe et al., 2006). Recently, we have further substantiated
the above ﬁndings showing that VV-HIV priming induces HIV-
speciﬁc CD8þ T cells of lower avidity compared to FPV-HIV
priming (Wijesundara et al., 2014). Interestingly, the current data
demonstrate that i.n. VV-HIV or MVA-HIV priming recruit higher
numbers of CD11b CD103þ DCs to the lung mucosae compared
to i.n. FPV-HIV vaccination and this CD103þ subset induces lower
avidity T cell responses. Interestingly, migratory CD11b CD103þ
(CD8α) DCs have shown to stimulate poor memory CD8þ T cell
proliferation (Belz et al., 2007; Waithman et al., 2007). Thus, we
speculate that CD103þ LDCs present higher amounts of antigens
to CD8þ T cells (Ho et al., 2011) that results in creation of a low
avidity T cell repertoire that gets expanded following the booster
immunization.
Different DC subsets recruited to the lung mucosae have been
shown to imprint the T cells with different functional capabilities
(Ballesteros-Tato et al., 2010; Furuhashi et al., 2012; Kim and
Braciale, 2009). This may also explain why a recent phase I clinical
trial using MVA-HIV prime followed by FPV-HIV booster vaccina-
tion strategy elicited poor immune outcomes (Keefer et al., 2011).
Furthermore, rhesus monkeys vaccinated with the canarypox virus
(genus Avipoxvirus) vector-based vaccine ALVAC has shown to
induce qualitatively distinct serum cytokine and chemokine pro-
ﬁles compared to the vaccinia virus-based vectors MVA and
NYVAC (Teigler et al., 2014) which is in agreement with the our
current rFPV ﬁndings. rMVA although highly attenuated still
retains viral genes that are involved in host immune response
evasion, and deletion of genes encoding MVA184R/B16R IL-1β
binding protein(Staib et al., 2005), MVA153L/A41L chemokine
binding protein (Clark et al., 2006), MVA019L/C6L inhibitor of
IFN-β induction (Garcia-Arriaza et al., 2011) or MVA008L/C12L
gene that encoded for IL-18 binding protein (Falivene et al., 2012)
can improve vaccine efﬁcacy. The MVA-HIV and VV-HIV vectors
used in the current study expressed these viral immune modula-
tors (virokine and viroreceptors) and we speculate that expression
of one or more of these factors could negatively inﬂuence the
induction of optimal antiviral Th1 mediated immunity, speciﬁcally
resulting in the induction of poorer quality CD8þ T cell immunity
by recruiting CD11b CD103þ DCs. In contrast, FPV has evolved to
interact with the avian immune system and may express immune
regulators that are ineffective at inhibiting mammalian Th1
immunity enabling the recruitment of CD11bþ CD103 DCs and
the induction of higher quality CD8þ T cell immunity. Further-
more, it could also be that compared to replication-deﬁcient FPV,
VV persist longer in-vivo delivering higher dose of antigen,
resulting in enhanced peptide-MHC presentation by DCs inducing
a T cell repertoire bias towards lower avidity. In the context of
MVA, we have found that the expression kinetics of replicative
defective FPV and MVA are very similar (Trivedi et al., unpublished
observations) and thus the differences in immune stimulation
observed could most likely due to the intrinsic genetic differences
of the two viruses.
It is now well established that CD11b CD103þ LDCs can
migrate to lymph nodes and induce differential adaptive immune
response depending on the virus infection present (Beauchamp et
al., 2012). Current data indicate that i.n. MVA-HIV or VV-HIV
immunization induces a much greater numbers of CD11b
CD103þ DCs in the lung mucosae compared to i.n. FPV-HIV
delivery. Following vaccinia virus infection, CD8α-expressing
CD103þ LDCs (CD8þ CD103þ) have been detected in the lung-
draining lymph node and these have shown to be less competent
in CD8þ T cell activation then their CD8α negative counterparts
(Beauchamp et al., 2010, 2012). Thus, the differences in functional
capabilities of the CD11b CD103þ LDC population could also be
attributed to the differential expression of CD8α on this DC subset
and therefore priming distinctly different T-cell responses result-
ing in varying immune outcomes. Unfortunately, unlike the
CD11bþ CD103 LDC subset, due to the small sample size further
characterization of this CD11b CD103þ LDCs subset was inher-
ently difﬁcult.
Our previous studies have demonstrated that i.n. priming with
FPV-HIV IL-13Rα2 was essential for the induction of high avidity
HIV-speciﬁc CD8þ T cell repertoire, whereas IL-13Rα2 adjuvant
co-expressed in the booster vaccination induced CD8þ T cell of
similar avidities to the standard unadjuvanted FPV-HIV vaccine
(Ranasinghe et al., 2013). We have now established that following
the IL-13Rα2 adjuvanted vaccine the recruitment of CD11bþ
CD103 DCs to the lung mucosae were much higher in magnitude
compared to the standard vaccination. Furthermore, following
IL-4Rα antagonist adjuvanted vaccination the numbers of CD11bþ
CD103 DC recruited to the lung mucosae were further enhanced.
Current ﬁndings suggest that the latter vaccine can induce
excellent high-avidity HIV-speciﬁc CD8þ T cells by differentially
regulating DCs, speciﬁcally by enhancing the CD11bþ CD103 DCs
and dampening the CD11b CD103þ DCs recruited to the vaccina-
tion site. The T cell avidity tetramer dissociation data demonstrate
that the presence of CD11b CD103þ DCs can have a detrimental
impact on induction of high avidity CD8þ T cells. The impact of
IL-4 on the activation and function of DCs has been reported in the
literature (Cook et al., 2012; Jenkins et al., 2013), it has been shown
that the ability to respond to IL-4 is critical for optimal Th1 or Th2
priming by DCs through modulation of IL-12/IL-10 or resistin-like
molecule α (RELMα) production respectively. Our data suggest
that IL-4 and IL-13 cytokine depleted cell milieu at the lung
mucosae can facilitate effective DC-mediated induction of robust
Th1 immunity.
In conclusion, our data demonstrate that unlike other poxviral
vectors rFPV is able to induce favorable antigen -speciﬁc CD8þ T
cell immunity by modulating the lung derived DCs. Similarly,
priming vaccination cell milieu plays a critical role in determining
the efﬁcacy/avidity of a vaccine. Speciﬁcally our current ﬁndings
indicate that (i) i.n delivery of FPV-HIV-IL-13Rα2 and/or IL-4Rα
antagonist adjuvanted vaccines recruit elevated percentages of
CD11bþ CD103 cDCs to the vaccination site suggesting that the
STAT6 pathway and /or IL-13 signaling via the IL-13Rα2 mem-
brane-bound receptor most likely play an important role in the DC
recruitment to the vaccination site, (ii) i.n. delivery of rMVA and
rVV enhances CD11b CD103þ DCs compared to rFPV delivery and
(iii) this CD11b CD103þ DCs plays a critical role in dampening
the HIV-speciﬁc CD8þ T cell avidity. Collectively, the ﬁndings
highlight the importance of understanding the fundamental
mechanisms by which inherent properties of different vaccine
vectors and adjuvants modulate antigen-speciﬁc immunity at the
vaccination site prior to clinical evaluation of these vector-based
vaccines.
Materials and methods
Mice
Pathogen-free 6–8 weeks old female BALB/c WT and BALB/c
IL-13 −/− mice were all purchased from the Australian Phenomics
Facility, The Australian National University (ANU). All animals
were maintained and experiments were performed in accordance
with the Australian NHMRC guidelines within the Australian
Code of Practice for the Care and Use of Animals for Scientiﬁc
Purposes and in accordance with guidelines approved by the ANU
Animal Experimentation and Ethics Committee (AEEC), protocol
number A2011/018. All animals were monitored daily; infected
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mice were scored for signs of illness. Animals were ethically
euthanized using cervical dislocation in accordance with the
above AEEC approved protocols.
Vaccines used in this study
Recombinant poxvirus vaccines were constructed as described
previously. Speciﬁcally, the standard FPV-HIV vaccine contained
modiﬁed AE clade gag, pol, env, tat and rev genes (Coupar et al.,
2006). The recombinant viruses co-expressing the HIV gag/pol
(mut) and mouse IL-13Rα2 soluble form or mouse IL-4Rα antago-
nist (IL-4C118 gene) were constructed using parent virus FPV-HIV
as described previously (Jackson et al., 2014a; Ranasinghe et al.,
2013). Recombinant VV-HIV (Coupar et al., 2006) and MVA-HIV
expressed the HIV gag/pol (mut) genes. The expression of the
inserted genes was evaluated by PCR and SDS-PAGE analysis for all
constructs used in this study. Immediately prior to delivery, these
recombinant vaccines were diluted in phosphate buffered saline
and sonicated to obtain a homogeneous viral suspension as
described before (Ranasinghe et al., 2006, 2013).
Immunoﬂuorescent staining
Mice were immunized intranasally (i.n.) with 2107 pfu FPV-
HIV and/ IL-13Rα2 adjuvanted vaccine at 24 h post vaccination
lungs were harvested. After surface washing with 1 phosphate
buffer saline (PBS), murine tissues were rapidly frozen in Tissue-
TekR Optimum Cutting Temperature Compound (ProSciTech, Aus-
tralia) using solid CO2. These tissue samples were stored at 80 1C
until processed for ﬂuorescence evaluation. For immunoﬂuores-
cent staining, lung sections, 7 mm thick were ﬁxed in ice-cold
acetone for 5 min at room temperature and washed with PBS for
5 min. To reduce non-speciﬁc staining, the sections were incu-
bated with anti-mouse CD16/CD32 Fc Block (BD Biosciences, USA)
diluted in 2% bovine serum albumin for 15 min, followed by PE
conjugated CD11b (Biolegend, USA), biotin conjugated CD11c
(N418 clone, Biolegend, USA) and APC conjugated MHCII I-Ad
antibody (e-Biosciences, USA) staining for 90 min at room tem-
perature. Following two washes with PBS for 5 min, secondary
antibody streptavidin brilliant violet 421 (Biolegend, USA) was
added to sections for 1 h. After the ﬁnal wash with PBS, the
sections were mounted with vectashield (Vector Laboratories,
USA) and images were captured using Leica TCS SP5 confocal
microscope (Leica, Germany).
Evaluation of antigen presenting cells using FACS
BALB/c were immunized with 5106 pfu control FPV-HIV, VV-
HIV or MVA-HIV vaccines and a second group of BALB/c mice were
immunized with the FPV-HIV IL-13Rα2 or the FPV-HIV IL-4Rα
antagonist adjuvanted vaccines. Also group of IL-13 KO animals
were immunized with standard FPV-HIV vaccine. 24 h post-
vaccination, mice were euthanized and lungs were collected and
single cell suspensions were prepared as described previously.
(Ranasinghe et al., 2011, 2013) From each sample 2106 cell
aliquots were prepared, and cells were incubated with anti-mouse
CD16/CD32 Fc Block antibody (BD Biosciences, USA), for 20 min at
4 1C and cells then were surface stained with APC conjugated
MHCII I-Ad (e-Biosciences, USA), CD8 APC-eFluor780 (53–6.7
clone, ebiosciences, USA), B220 PercpCy5.5 (RA3-6B2 clone,
e-Biosciences, USA), CD11b AlexaFluor 700 (M1170 clone, Biole-
gend, USA), F4/80 PE Cy7 (BM8 clone, Biolegend, USA), CD103 FITC
(2E7 clone, e-Biosciences, USA), CD86 PE (GL1 clone, BD Bios-
ciences, USA), biotin conjugated CD11c (N418 clone, Biolegend,
USA), followed by streptavidin Brilliant violet 421 (Biolegend,
USA). In addition, to discriminate moDCs from cDCs, CD64
PercpCy5.5 (X54-5/7.1 clone, Biolegend, USA), FcεR1α FITC (MAR-
1 clone, Biolegend, USA) and Ly-6C BV605 (AL-21 clone, BDbios-
ciences) were used. AMFs were identiﬁed using Siglec-F PE (E50-
2440 clone, BD Biosciences, USA). Cells were ﬁxed and total 106
gated events per sample were collected using Fortessa ﬂow
cytometer (Becton Dickinson, San Diego, CA), and results were
analyzed using Cell Quest Pro/FlowJo software.
Adoptive transfer of DC subsets, tetramer staining and dissociation
assays
BALB/c mice (n¼14) were i.n. immunized with 5106 pfu
FPV-HIV IL-4Rα antagonist adjuvanted vaccine and 24 h post
immunization lung single cell suspensions were prepared. Follow-
ing overnight incubation at 37 1C with 5% CO2 (for recovery as we
have observed that digestion can down regulate the expression of
cell surface markers) cells were stained with APC conjugated
MHCII IAd, CD11b AlexaFluor 700, CD103 FITC, CD11c biotin
followed by streptavidin brilliant violet 421 as mentioned pre-
viously. CD11bþ CD103 and CD11b CD103þ LDCs were sorted,
1105 cells in 20 ml sterile protein-free PBS were adoptively
transferred i.n. to naive recipient mice (n¼3 to 4 per group).
20 ml PBS was given to another group and this group of mice were
used as controls. 16 h post transfer, the recipient mice were
primed i.n. with 1107 pfu FPV-HIV and two weeks later boosted
with 2107 pfu of MVA-HIV (Note that studies in our laboratory
have shown that rVV and rMVA booster induce similar immune
outcomes).
To measure the CD8þ T cell avidity, mice were euthanized 14
days post booster immunization, spleens were removed and single
cell suspensions were prepared as described previously. Next
2106 splenocytes were stained with APC conjugated immuno-
dominant H2-KdGag197–205 tetramer (Mata et al., 1998) together
with anti-CD8α FITC antibody at room temperature and dissocia-
tion assays were performed as described previously (Ranasinghe
et al., 2013, 2007) (the tetramers were synthesized at the
Bio-Molecular Resource Facility (BRF) at JCSMR / ANU). Plate was
conﬁgured to have ﬁve time points per sample (0–60 min). 50 mg/
ml H-2Kd competitive antibody (BD PharMigen, San Diego, Cali-
fornia) was added to each well to prevent tetramer re-binding and
plates were incubated at 37 1C, 5% CO2. At each time point, cells
were transferred into ice-cold PBS to stop the reaction, washed
and resuspended in 100 ml of FACS buffer containing 0.5% para-
formaldehyde. A total of 500,000 events were acquired on a
Fortessa ﬂow cytometer (Becton Dickinson, San Diego, California),
and results were analyzed using Cell Quest Pro/ Flow Jo software.
The % tetramer dissociation was calculated as in (Ranasinghe et al.,
2007) as follows: if at time zero the KdGag197–205 tetramerþ CD8þ
T cell population was (a) and at 10 min it was (b). The dissociation
rate was calculated as 100 - [(100/a) x b]. This was calculated for
each time point.
Statistical analysis of data
Standard deviation (7SD) or standard error of the mean
(7SEM) was calculated and p-values were determined using a
two-tailed, two sample equal variance Student's t-test or one way
ANOVA with Newman Keuls multiple comparison post-test. The
p-values less than 0.05 were considered signiﬁcant. Except where
stated, to obtain enough cell numbers in each experiment the
lungs were pooled from three animals, and the experiments were
repeated 3–5 times. Therefore, the statistics represent average of
3–5 experiments.
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